Can a common blood pressure pill shield diabetic kidneys from contrast dye?
NCT ID NCT07291375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a low dose of oral amlodipine can prevent kidney damage caused by contrast dye in diabetic patients in the intensive care unit. The trial will enroll 40 adults with diabetes and normal kidney function who are stable enough for the procedure. Researchers will measure creatinine levels before and for two days after contrast exposure to see if the drug offers protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTRAST-INDUCED NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Quitting smoking may also ward off diabetes — a trial puts the dual strategy to the test
- Could a simple clinic Check-In change catch hidden high blood pressure and diabetes?
- Decades-Long study of 121,700 nurses aims to uncover hidden heart disease triggers
- Could donating blood help control diabetes and fatty liver?
- Phone-Based fitness program aims to cut heart disease in african american women
- Could a wearable sensor replace Finger-Sticks for hospital diabetes care?